Arrowhead Deferred Long Term Liab vs Net Tangible Assets Analysis

ARWR Stock

USD 25.00 0.04 0.16%

Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Deferred Long Term Liab and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Deferred Long Term Liab vs Net Tangible Assets

Deferred Long Term Liab vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Deferred Long Term Liab account and Net Tangible Assets. At this time, the significance of the direction appears to have very week relationship.

The correlation between Arrowhead Pharmaceuticals' Deferred Long Term Liab and Net Tangible Assets is 0.2. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Arrowhead Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Deferred Long Term Liab and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Arrowhead Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Deferred Long Term Liab i.e., Arrowhead Pharmaceuticals' Deferred Long Term Liab and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 05/17/2024, Enterprise Value is likely to grow to about 3.3 B, while Selling General Administrative is likely to drop slightly above 79.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	243.2M	228.2M	262.5M	275.6M
Total Revenue	243.2M	240.7M	276.8M	290.7M

Gross Profit Total Revenue

Arrowhead Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.9	-0.68	0.26	0.78	0.87	0.04	-0.92	0.79	0.66	0.93	0.76	0.54	0.24	0.76	0.87	-0.72	0.67	0.95	0.92	0.85	0.53	0.74	0.26	0.36	0.88
Short Long Term Debt Total	0.9		-0.92	-0.12	0.5	0.99	0.38	-0.88	0.9	0.38	0.97	0.93	0.17	-0.1	0.63	0.72	-0.91	0.7	0.88	0.95	0.97	0.15	0.83	0.24	0.02	0.97
Other Current Liab	-0.68	-0.92		0.42	-0.28	-0.94	-0.52	0.7	-0.91	-0.16	-0.87	-0.97	0.18	0.36	-0.42	-0.5	0.87	-0.5	-0.71	-0.77	-0.94	0.2	-0.84	-0.02	0.28	-0.85
Total Current Liabilities	0.26	-0.12	0.42		0.42	-0.2	-0.72	-0.14	-0.24	0.63	-0.06	-0.35	0.82	0.78	0.26	0.33	0.26	0.16	0.13	0.13	-0.22	0.83	0.01	0.28	0.98	-0.05
Total Stockholder Equity	0.78	0.5	-0.28	0.42		0.49	-0.4	-0.63	0.54	0.8	0.63	0.43	0.64	0.37	0.7	0.78	-0.17	0.17	0.8	0.48	0.52	0.64	0.51	-0.14	0.39	0.41
Property Plant And Equipment Net	0.87	0.99	-0.94	-0.2	0.49		0.42	-0.86	0.94	0.33	0.98	0.97	0.07	-0.12	0.61	0.7	-0.89	0.62	0.88	0.91	0.99	0.06	0.82	0.13	-0.07	0.95
Net Debt	0.04	0.38	-0.52	-0.72	-0.4	0.42		-0.17	0.32	-0.71	0.31	0.46	-0.61	-0.38	-0.17	-0.16	-0.56	0.26	0.06	0.29	0.41	-0.62	0.04	0.12	-0.62	0.42
Retained Earnings	-0.92	-0.88	0.7	-0.14	-0.63	-0.86	-0.17		-0.78	-0.51	-0.89	-0.76	-0.42	-0.09	-0.83	-0.91	0.78	-0.7	-0.94	-0.9	-0.84	-0.41	-0.69	-0.3	-0.23	-0.88
Accounts Payable	0.79	0.9	-0.91	-0.24	0.54	0.94	0.32	-0.78		0.36	0.94	0.97	-0.05	-0.14	0.6	0.66	-0.73	0.39	0.86	0.76	0.97	-0.06	0.84	-0.16	-0.17	0.81
Cash	0.66	0.38	-0.16	0.63	0.8	0.33	-0.71	-0.51	0.36		0.43	0.24	0.75	0.33	0.65	0.71	-0.13	0.27	0.62	0.44	0.33	0.76	0.56	0.06	0.63	0.32
Non Current Assets Total	0.93	0.97	-0.87	-0.06	0.63	0.98	0.31	-0.89	0.94	0.43		0.94	0.2	0.04	0.66	0.76	-0.82	0.58	0.93	0.92	0.98	0.19	0.81	0.09	0.05	0.93
Non Currrent Assets Other	0.76	0.93	-0.97	-0.35	0.43	0.97	0.46	-0.76	0.97	0.24	0.94		-0.13	-0.21	0.52	0.59	-0.81	0.43	0.81	0.79	0.99	-0.14	0.83	-0.09	-0.25	0.85
Cash And Short Term Investments	0.54	0.17	0.18	0.82	0.64	0.07	-0.61	-0.42	-0.05	0.75	0.2	-0.13		0.53	0.51	0.59	-0.06	0.46	0.4	0.38	0.02	1.0	0.11	0.51	0.84	0.23
Net Receivables	0.24	-0.1	0.36	0.78	0.37	-0.12	-0.38	-0.09	-0.14	0.33	0.04	-0.21	0.53		0.12	0.14	0.25	-0.04	0.13	0.12	-0.1	0.55	-0.14	0.03	0.74	-0.02
Common Stock Total Equity	0.76	0.63	-0.42	0.26	0.7	0.61	-0.17	-0.83	0.6	0.65	0.66	0.52	0.51	0.12		0.93	-0.45	0.49	0.85	0.64	0.6	0.51	0.55	0.16	0.28	0.6
Common Stock Shares Outstanding	0.87	0.72	-0.5	0.33	0.78	0.7	-0.16	-0.91	0.66	0.71	0.76	0.59	0.59	0.14	0.93		-0.52	0.57	0.92	0.75	0.68	0.59	0.66	0.21	0.38	0.69
Inventory	-0.72	-0.91	0.87	0.26	-0.17	-0.89	-0.56	0.78	-0.73	-0.13	-0.82	-0.81	-0.06	0.25	-0.45	-0.52		-0.82	-0.66	-0.9	-0.84	-0.04	-0.64	-0.47	0.09	-0.95
Other Current Assets	0.67	0.7	-0.5	0.16	0.17	0.62	0.26	-0.7	0.39	0.27	0.58	0.43	0.46	-0.04	0.49	0.57	-0.82		0.53	0.84	0.52	0.44	0.41	0.84	0.32	0.81
Other Stockholder Equity	0.95	0.88	-0.71	0.13	0.8	0.88	0.06	-0.94	0.86	0.62	0.93	0.81	0.4	0.13	0.85	0.92	-0.66	0.53		0.84	0.88	0.4	0.76	0.07	0.2	0.82
Total Liab	0.92	0.95	-0.77	0.13	0.48	0.91	0.29	-0.9	0.76	0.44	0.92	0.79	0.38	0.12	0.64	0.75	-0.9	0.84	0.84		0.86	0.37	0.72	0.46	0.27	0.98
Property Plant And Equipment Gross	0.85	0.97	-0.94	-0.22	0.52	0.99	0.41	-0.84	0.97	0.33	0.98	0.99	0.02	-0.1	0.6	0.68	-0.84	0.52	0.88	0.86		0.01	0.83	0.01	-0.11	0.91
Total Current Assets	0.53	0.15	0.2	0.83	0.64	0.06	-0.62	-0.41	-0.06	0.76	0.19	-0.14	1.0	0.55	0.51	0.59	-0.04	0.44	0.4	0.37	0.01		0.11	0.5	0.85	0.22
Short Term Debt	0.74	0.83	-0.84	0.01	0.51	0.82	0.04	-0.69	0.84	0.56	0.81	0.83	0.11	-0.14	0.55	0.66	-0.64	0.41	0.76	0.72	0.83	0.11		-0.05	0.12	0.72
Common Stock	0.26	0.24	-0.02	0.28	-0.14	0.13	0.12	-0.3	-0.16	0.06	0.09	-0.09	0.51	0.03	0.16	0.21	-0.47	0.84	0.07	0.46	0.01	0.5	-0.05		0.42	0.42
Current Deferred Revenue	0.36	0.02	0.28	0.98	0.39	-0.07	-0.62	-0.23	-0.17	0.63	0.05	-0.25	0.84	0.74	0.28	0.38	0.09	0.32	0.2	0.27	-0.11	0.85	0.12	0.42		0.1
Non Current Liabilities Total	0.88	0.97	-0.85	-0.05	0.41	0.95	0.42	-0.88	0.81	0.32	0.93	0.85	0.23	-0.02	0.6	0.69	-0.95	0.81	0.82	0.98	0.91	0.22	0.72	0.42	0.1

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Other Current Liab	13.5M	23.8M	(5.6M)	(46.4M)	(53.4M)	(50.7M)
Total Current Liabilities	40.7M	146.5M	74.1M	866K	995.9K	946.1K
Total Stockholder Equity	461.8M	408.8M	106.0M	271.3M	312.0M	327.6M
Property Plant And Equipment Net	47.0M	66.0M	168.6M	335.6M	385.9M	405.2M
Net Debt	(122.4M)	(158.9M)	(26.4M)	4.3M	3.9M	4.0M
Retained Earnings	(503.8M)	(644.7M)	(820.8M)	(1.0B)	(923.4M)	(877.3M)
Accounts Payable	6.8M	9.5M	2.9M	35.9M	41.2M	43.3M
Cash	143.6M	184.4M	108.0M	110.9M	127.5M	133.9M
Non Current Assets Total	200.1M	325.6M	315.5M	654.7M	752.9M	790.5M
Non Currrent Assets Other	265.4K	272K	29.1M	361.9M	416.2M	437.0M
Cash And Short Term Investments	315.5M	367.8M	376.4M	110.9M	127.5M	83.7M
Net Receivables	327.4K	661.4K	845.7K	10.3M	1.4M	0.0
Common Stock Total Equity	187.9K	194.7K	197K	198K	227.7K	239.1K
Common Stock Shares Outstanding	100.7M	103.7M	105.4M	106.8M	122.8M	128.9M
Liabilities And Stockholders Equity	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Inventory	3.3M	4.3M	4.4M	(21.6M)	(19.5M)	(18.5M)
Other Current Assets	1.8M	2.2M	20.2M	7.1M	8.1M	8.6M
Other Stockholder Equity	965.4M	1.1B	820.9M	1.3B	1.5B	1.6B
Total Liab	60.7M	301.3M	586.0M	478.4M	550.1M	577.7M
Property Plant And Equipment Gross	47.0M	88.9M	110.3M	377.5M	434.1M	455.8M
Total Current Assets	322.4M	384.6M	376.4M	110.9M	127.5M	85.9M
Accumulated Other Comprehensive Income	18.4K	(69K)	(136K)	(3.2M)	(2.9M)	(2.8M)
Short Term Debt	1.1M	2.3M	2.8M	10.6M	12.1M	12.8M
Common Stock	194.7K	197K	106.0M	200K	230K	218.5K
Current Deferred Revenue	19.3M	111.1M	74.1M	866K	995.9K	946.1K
Non Current Liabilities Total	20.0M	154.8M	511.9M	477.5M	549.2M	576.6M
Property Plant Equipment	30.9M	48.7M	110.3M	335.6M	385.9M	405.2M
Other Assets	68.9M	96.8M	218K	210K	241.5K	229.4K
Short Term Investments	171.9M	183.4M	268.4M	292.7M	336.6M	353.5M
Intangible Assets	15.4M	13.7M	12.0M	10.3M	11.8M	10.2M
Other Liab	8.7M	41.4M	190.3M	56.0M	64.3M	67.6M
Net Tangible Assets	446.4M	395.2M	398.5M	261.1M	300.2M	202.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:

How To Invest In Arrowhead

Details

Is Arrowhead Stock a good investment?

Details

What is Arrowhead Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Arrowhead Stock analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets

Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.098

Earnings Share

(4.23)

Revenue Per Share

0.319

Quarterly Revenue Growth

(0.94)

Return On Assets

(0.32)

The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arrowhead Deferred Long Term Liab vs Net Tangible Assets Analysis

Deferred Long Term Liab vs Net Tangible Assets

Deferred Long Term Liab vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Tangible Assets

Arrowhead Pharmaceuticals fundamental ratios Correlations

Arrowhead Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arrowhead Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Arrowhead Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Non Currrent Assets Other
Current Deferred Revenue	+ 0.98	Total Current Liabilities
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net

Non Currrent Assets Other	- 0.97	Other Current Liab
Non Current Liabilities Total	- 0.95	Inventory
Other Stockholder Equity	- 0.94	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Other Current Liab
Property Plant And Equipment Net	- 0.94	Other Current Liab
Other Current Liab	- 0.92	Short Long Term Debt Total